[1] |
HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong.
Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
|
[2] |
WANG Juan, LIU Weiying, YE Yucai, FU Wenli, ZHANG Sha, LI Leping.
Research progress of norepinephrine reuptake inhibitor combined with antimuscarinic in the treatment of obstructive sleep apnea
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 714-720.
|
[3] |
SHEN Jiaqing, LIU Yi.
Mechanism of tyrosine kinase 2 inhibitors in treatment of plaque psoriasis and their progress in clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 323-330.
|
[4] |
LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi .
PDE4 inhibitors serve as therapeutic targets for pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 355-360.
|
[5] |
HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle.
Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
|
[6] |
WANG Jinhuo, GAO Xinyue, GUO Jianrong.
Effect of COX-2 inhibitors on postoperative delirium in elderly patients undergoing orthopedic surgery and its possible mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 863-869.
|
[7] |
HE Xueru, FU Yuhao, XUN Xuejiao, CUI Yanjun, DONG Zhanjun.
Advances in uridine diphosphate glucuronosyltransferase-mediated drug interactions with tyrosine kinase inhibitors
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 936-945.
|
[8] |
SUN Ying, YU Qin.
Research progress on the imbalance of coagulation and fibrinolysis system and the pathogenesis and treatment of idiopathic pulmonary interstitial fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 689-695.
|
[9] |
LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi.
Integrins targeting αv are used as drug targets for pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 709-714.
|
[10] |
LIU Yizhen, REN Lingxuan, YANG Jianjun, HE Jianyu, LIU Xiaojun, WANG Long, LIN Rong.
Study on the screening of active constituents of Taohong Siwu Decoction and the protective effect of ferulic acid on myocardial injury
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 505-515.
|
[11] |
PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng.
Progress of pharmacotherapy for heart failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
|
[12] |
WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming.
Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
|
[13] |
LI Yuanfang, CUI Zhaoqiang.
Treatment of hypertension complicated with hyperuricemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
|
[14] |
XU Jianfei, LIN Li.
Research progress in pharmacological and non-pharmacological treatments of hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
|
[15] |
KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng.
Angiotensin receptor neprilysin inhibitor in elderly with hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.
|